Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

Sanofi: Dupixent website materials used outdated prescribing information and a misleading asthma statement (AUTH/3402/10/20)

Sanofi’s Dupixent website hosted a NICE guidance resource with Oct 2017 prescribing information and an HCP guide stating…

8 Mar 2026

Allergan social media tagging of HCP/clinic Instagram accounts mentioning Botox: no breach on appeal (AUTH/3441/12/20)

Ex-employee alleged Allergan product specialists promoted Botox via Instagram tags/hashtags linking to HCP/clinic posts. Panel found breaches, but…

8 Mar 2026

LEO Pharma UK – Undeclared transfers of value (Disclosure UK) (AUTH/3593/12/21)

LEO made a voluntary admission after five 2020 transfers of value (4 HCP, 1 HCO) were omitted from…

8 Mar 2026

CSL Vifor: NHS IV iron service alleged to be disguised promotion for Ferinject (AUTH/3706/11/22) – No breach

Ex-employee alleged CSL Vifor’s non-promotional NHS service was targeted to Ferinject-using hospitals and amounted to disguised promotion/inducement. Panel…

8 Mar 2026

AUTH/3717/12/22: Public complaint about weight-loss media coverage – Novo Nordisk (Sunday Times interview led to breaches)

Five weight-loss media articles were complained about. Novo Nordisk was not responsible for four. One Sunday Times interview…

8 Mar 2026

A. Menarini breached Clause 26.1 after third-party X post showed β€œInvokana canagliflozin tablets” at diabetes conference

An events business employee posted a public X photo where β€œInvokana canagliflozin tablets” was legible on Menarini’s stand.…

8 Mar 2026

AUTH/3239/8/19: Pharmacist v Colonis Pharma Limited – promotion of Melatonin Oral Solution and off-label implication

A pharmacist complained a launch letter promoted off-label use of Melatonin 1mg/ml Oral Solution. The Panel ruled the…

8 Mar 2026

AUTH/2115/4/08 Roche v GlaxoSmithKline: Press releases for Tykerb/Tyverb (lapatinib) on corporate website

Roche challenged two GSK corporate press releases about lapatinib (Tykerb/Tyverb). The Panel found one release misleading on adverse…

8 Mar 2026

Allergan v Merz Pharma (AUTH/2270/10/09): β€œAt least as effective as Botox” claim from non-inferiority studies ruled misleading

Merz promoted Xeomin as β€œAt least as effective as Botox with a similar safety profile” on an exhibition…

8 Mar 2026

AUTH/2311/4/10: Anonymous v AstraZeneca – Seroquel meeting alleged off-label promotion (No breach)

Anonymous alleged an AstraZeneca meeting misled attendees and promoted Seroquel for borderline personality disorder. Panel found no evidence…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training